Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Caliway Biopharmaceuticals CoTPE:6919 -3.30%55 PS Ratio is 5,242.11 as of Aug. 31, 2026, which is 99% above its 10-year median of 2,640.63. GuruFocus rates TPE:6919 with a GF Score™ of 55/100 and a GF Value™ of NT$59.00 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 934 Biotechnology companies, Caliway Biopharmaceuticals Co ranks worse than 98.72% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Caliway Biopharmaceuticals Co's share price is NT$99.60.
Caliway Biopharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.02. Hence, Caliway Biopharmaceuticals Co's PS Ratio for today is 5,242.11.
The historical rank and industry rank for Caliway Biopharmaceuticals Co's PS Ratio or its related term are showing as below:
TPE:6919'
s PS Ratio Range Over the Past 10 Years
Min: 537.5 Med: 2640.63 Max: 11378.4
Current: 5242.11
During the past 7 years, Caliway Biopharmaceuticals Co's highest PS Ratio was 11378.40. The lowest was 537.50. And the median was 2640.63.
TPE:6919's PS Ratio is ranked worse than 98.72% of 934
companies
in the Biotechnology industry
Industry Median: 9.52
vs TPE:6919: 5242.11
During the past 7 years, Caliway Biopharmaceuticals Co's highest 3-Year average Revenue per Share Growth Rate was 31.50% per year. The lowest was -40.80% per year. And the median was 11.20% per year.
Caliway Biopharmaceuticals Co (TPE:6919) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Caliway Biopharmaceuticals Co PS Ratio Related Terms
Caliway Biopharmaceuticals Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Caliway Biopharmaceuticals Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caliway Biopharmaceuticals Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Caliway Biopharmaceuticals Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Caliway Biopharmaceuticals Co's PS Ratio falls into.
Caliway Biopharmaceuticals Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Caliway Biopharmaceuticals Co's Share Price of today is NT$99.60. Caliway Biopharmaceuticals Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Caliway Biopharmaceuticals Co (TPE:6919) has a PS Ratio of 5,242.11 as of Aug. 31, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Caliway Biopharmaceuticals Co and its competitors. This is 99% above median its historical median of 2,640.63. Over the past decade, Caliway Biopharmaceuticals Co's PS Ratio has ranged from 537.50 to 11,378.40. According to the industry distribution chart, Caliway Biopharmaceuticals Co ranks #922 out of 934 companies in the Biotechnology industry, placing it in the top 98.7%.
Is Caliway Biopharmaceuticals Co's PS Ratio too high?
Caliway Biopharmaceuticals Co's current PS Ratio of 5,242.11 is 99% above median its 10-year median of 2,640.63. Over the past 10 years, this metric has ranged from a low of 537.50 to a high of 11,378.40. The Biotechnology industry median PS Ratio is 9.52. Caliway Biopharmaceuticals Co's value of 5,242.11 is 54964.2% above this industry median. Based on the distribution chart, Caliway Biopharmaceuticals Co ranks #922 out of 934 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Caliway Biopharmaceuticals Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caliway Biopharmaceuticals Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Caliway Biopharmaceuticals Co ranks #922 out of 934 companies for PS Ratio. This places Caliway Biopharmaceuticals Co in the lower half of its industry. The industry median PS Ratio is 9.52. Caliway Biopharmaceuticals Co's value of 5,242.11 is 54964.2% above this benchmark. Historically, Caliway Biopharmaceuticals Co's own PS Ratio has ranged from 537.50 to 11,378.40 over the past decade. While the company's 10-year median is 2,640.63 vs. the industry median of 9.52, Caliway Biopharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caliway Biopharmaceuticals Co's current PS Ratio of 5,242.11 is 54964.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Caliway Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caliway Biopharmaceuticals Co's current PS Ratio is 5,242.11, which is 99% above median its own 10-year median of 2,640.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caliway Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co (TPE:6919) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$59.00, compared to a current price of NT$99.60 — trading 68.8% above its estimated fair value. The current PS Ratio is 5,242.11, which is 99% above median its 10-year median of 2,640.63 and 54964.2% above the Biotechnology industry median of 9.52. Caliway Biopharmaceuticals Co's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Caliway Biopharmaceuticals Co (TPE:6919), the current PS Ratio is 5,242.11 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caliway Biopharmaceuticals Co (TPE:6919) Overvalued in 2026?
Based on GuruFocus' analysis, Caliway Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of NT$99.60 is trading 68.8% above its estimated GF Value™ of NT$59.00.
GuruFocus considers Caliway Biopharmaceuticals Co to be Significantly Overvalued.
Key valuation signals for TPE:6919:
PS Ratio: 5,242.11 (99% above median its 10-year median of 2,640.63)
GF Value™: NT$59.00 vs. price of NT$99.60 (68.8% above fair value)
Industry Position: 54964.2% above the Biotechnology median (#922 of 934)
No single metric tells the full story. See the TPE:6919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. The group has one operating segment, which is Healthy Food, and others.
55GF Score
Get the complete analysis for TPE:6919
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6919 has been successfully added to your 
